Psoriasis is characterized by hyperproliferation of keratinocytes and increased expression of integrins, but the pathological signaling pathway remains unknown. In August 15 Journal of Clinical ...

Yeast filamentous growth is a highly regulated cellular differentiation response, enabling cells to assume an elongated morphology when confronted with environmental stress or nutrient limitation.

A new research paper was published in Volume 18 of Aging-US on March 3, 2026, titled "P38 MAPK is involved in epigenetic regulation of fibrotic genes in replication induced senescence in lung ...

IMMUNORARE5: A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab ...

Erasca, Inc. presents promising preclinical data on ERAS-0015 and ERAS-4001 targeting RAS/MAPK pathway cancers at AACR meeting. Erasca, Inc. presented new preclinical data at the American Association ...

Pasithea Therapeutics Corp. has announced the successful enrollment and initial dosing of three subjects in Cohort 6 of its Phase 1 clinical trial for PAS-004, a candidate for treating ...

On March 4, 2026, Verastem posted an updated corporate presentation outlining its strategy around AVMAPKI FAKZYNJA co-pack for KRAS mutant recurrent low-grade serous ovarian cancer and its broader RAS ...

Neoadjuvant immunotherapy for oropharynx cancer: Correlative studies and long-term outcomes from the CIAO trial. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...

ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat. Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at ...